

Development of lead for intestinal gluco tonic therapeutics based on atypical PKC activation for treatment of metabolic syndrome

Yonsei University



METABOLIC	Hit
Product Type	Chemical Product
Indication	1st indication: Diabetes, type 1 and/or 2 2nd indication: Obesity
Target	Atypical Protein Kinase C (aPKC)
MoA(Mechanism of Action)	Binds to aPKC and activates its activity and GLUT1 translocation leading to excreting excess glucose outside of the body as a treatment for metabolic syndrome
Competitiveness	First In Class • The drug activates the novel mechanism found in intestine after bariatric metabolic surgery that has been proven to have prominent effect in controlling high glucose and over weight.
Development Stage	Hit
Route of Administration	Oral intake